Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy.
Identifieur interne : 001897 ( Ncbi/Curation ); précédent : 001896; suivant : 001898Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy.
Auteurs : Alexei Korchounov [Allemagne] ; Gregory BogomazovSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.
English descriptors
- KwdEn :
- Absenteeism, Antiparkinson Agents (therapeutic use), Catechols (therapeutic use), Disability Evaluation, Double-Blind Method, Drug Therapy, Combination, Employment, Female, Humans, Levodopa (therapeutic use), Male, Middle Aged, Nitriles (therapeutic use), Outcome Assessment (Health Care), Parkinson Disease (drug therapy), Parkinson Disease (psychology), Self Concept.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Catechols, Levodopa, Nitriles.
- drug therapy : Parkinson Disease.
- psychology : Parkinson Disease.
- Absenteeism, Disability Evaluation, Double-Blind Method, Drug Therapy, Combination, Employment, Female, Humans, Male, Middle Aged, Outcome Assessment (Health Care), Self Concept.
Abstract
The objective of this study was to test the impact of entacapone (ENT) addition to levodopa with a decarboxylase inhibitor (LD) in full-time-employed patients with Parkinson's disease (PD), focusing on retirement rates, medical absenteeism, self-perception of disability, as well as motor assessments of parkinsonism, motor fluctuations, and dyskinesias. Thirty full-time-employed PD patients (disease onset before age 60 years) and on optimized monotherapy with LD exhibiting minor motor fluctuations or dyskinesias were entered into a 2-year randomized double-blind placebo-controlled study of ENT adjunctive therapy. The outcome measures were the number of full-time-employed patients at study end, cumulative days of medical absenteeism, patient-completed disability assessments, diary records, and the Unified Parkinson's Disease Rating Scale-based measures of motor fluctuations and dyskinesias. LD + ENT treatment was associated with a lower retirement rate (2 [17%] of 12 vs. 6 [50%] of 12; P = 0.12), lower absenteeism rate (21.5 vs. 43.5 days; P < 0.0001), improved self-perception of disability progression over 2 years (change score 1.0 vs. 4.5; P < 0.0001), and lower scores for both motor fluctuations and dyskinesia assessments compared to LD monotherapy. In this pilot study, LD with ENT adjunctive therapy positively influenced employment rate over 2 years; this effect was associated with reduced motor complications and patient perceptions of stabilized disability.
DOI: 10.1002/mds.21123
PubMed: 17044084
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002A42
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002A42
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002D41
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001897
Links to Exploration step
pubmed:17044084Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy.</title><author><name sortKey="Korchounov, Alexei" sort="Korchounov, Alexei" uniqKey="Korchounov A" first="Alexei" last="Korchounov">Alexei Korchounov</name><affiliation wicri:level="1"><nlm:affiliation>Parkinson Clinic, Bad Nauheim, Germany. a.korchounov@parkinsonzentrum.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Parkinson Clinic, Bad Nauheim</wicri:regionArea><wicri:noRegion>Bad Nauheim</wicri:noRegion><wicri:noRegion>Bad Nauheim</wicri:noRegion><wicri:noRegion>Bad Nauheim</wicri:noRegion></affiliation></author><author><name sortKey="Bogomazov, Gregory" sort="Bogomazov, Gregory" uniqKey="Bogomazov G" first="Gregory" last="Bogomazov">Gregory Bogomazov</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="doi">10.1002/mds.21123</idno><idno type="RBID">pubmed:17044084</idno><idno type="pmid">17044084</idno><idno type="wicri:Area/PubMed/Corpus">002A42</idno><idno type="wicri:Area/PubMed/Curation">002A42</idno><idno type="wicri:Area/PubMed/Checkpoint">002D41</idno><idno type="wicri:Area/Ncbi/Merge">001897</idno><idno type="wicri:Area/Ncbi/Curation">001897</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy.</title><author><name sortKey="Korchounov, Alexei" sort="Korchounov, Alexei" uniqKey="Korchounov A" first="Alexei" last="Korchounov">Alexei Korchounov</name><affiliation wicri:level="1"><nlm:affiliation>Parkinson Clinic, Bad Nauheim, Germany. a.korchounov@parkinsonzentrum.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Parkinson Clinic, Bad Nauheim</wicri:regionArea><wicri:noRegion>Bad Nauheim</wicri:noRegion><wicri:noRegion>Bad Nauheim</wicri:noRegion><wicri:noRegion>Bad Nauheim</wicri:noRegion></affiliation></author><author><name sortKey="Bogomazov, Gregory" sort="Bogomazov, Gregory" uniqKey="Bogomazov G" first="Gregory" last="Bogomazov">Gregory Bogomazov</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Absenteeism</term><term>Antiparkinson Agents (therapeutic use)</term><term>Catechols (therapeutic use)</term><term>Disability Evaluation</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Employment</term><term>Female</term><term>Humans</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Nitriles (therapeutic use)</term><term>Outcome Assessment (Health Care)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term><term>Self Concept</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Catechols</term><term>Levodopa</term><term>Nitriles</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Absenteeism</term><term>Disability Evaluation</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Employment</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Outcome Assessment (Health Care)</term><term>Self Concept</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective of this study was to test the impact of entacapone (ENT) addition to levodopa with a decarboxylase inhibitor (LD) in full-time-employed patients with Parkinson's disease (PD), focusing on retirement rates, medical absenteeism, self-perception of disability, as well as motor assessments of parkinsonism, motor fluctuations, and dyskinesias. Thirty full-time-employed PD patients (disease onset before age 60 years) and on optimized monotherapy with LD exhibiting minor motor fluctuations or dyskinesias were entered into a 2-year randomized double-blind placebo-controlled study of ENT adjunctive therapy. The outcome measures were the number of full-time-employed patients at study end, cumulative days of medical absenteeism, patient-completed disability assessments, diary records, and the Unified Parkinson's Disease Rating Scale-based measures of motor fluctuations and dyskinesias. LD + ENT treatment was associated with a lower retirement rate (2 [17%] of 12 vs. 6 [50%] of 12; P = 0.12), lower absenteeism rate (21.5 vs. 43.5 days; P < 0.0001), improved self-perception of disability progression over 2 years (change score 1.0 vs. 4.5; P < 0.0001), and lower scores for both motor fluctuations and dyskinesia assessments compared to LD monotherapy. In this pilot study, LD with ENT adjunctive therapy positively influenced employment rate over 2 years; this effect was associated with reduced motor complications and patient perceptions of stabilized disability.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001897 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001897 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:17044084
|texte= Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:17044084" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |